

Toxicity, Pharmacokinetics, and Dose-Finding Study of Repetitive Treatment with the Humanized Anti-Interleukin 6 Receptor Antibody MRA in Rheumatoid Arthritis. Phase I/II Clinical Study

NORIIHIRO NISHIMOTO, KAZUYUKI YOSHIZAKI, KEIJI MAEDA, TARO KURITANI, HITOSHI DEGUCHI, BUNZO SATO, NOBUYUKI IMAI, MASAKI SUEMURA, TAKAHIRO KAKEHI, NOBUHIRO TAKAGI, and TADAMITSU KISHIMOTO

ABSTRACT. Objective. To evaluate the safety and pharmacokinetics of multiple infusions of a humanized anti-interleukin-6 (IL-6) receptor antibody, MRA, in patients with rheumatoid arthritis (RA).

Methods. In an open label trial, 15 patients with active RA were intravenously administered 3 doses (2, 4, or 8 mg/kg) of MRA biweekly for 6 weeks, and pharmacokinetics were assessed. Patients continued on MRA treatment for 24 weeks, and were then assessed for safety and efficacy.

Results. The treatment was well tolerated at all doses with no severe adverse event. Increased total serum cholesterol was detected as an MRA-related reaction in 10/15 (66%) patients. There was no statistically significant difference in the frequency of adverse events among the 3 dose groups. There were no new observations of antinuclear antibody or anti-DNA antibody, and no anti-MRA antibody was detected. The $T_{1/2}$ increased with repeated doses and as the dose increased. $T_{1/2}$ after the 3rd dose of 8 mg/kg reached 241.8 ± 71.4 h. In 12/15 (80%) patients whose serum MRA was detectable during the treatment period, objective inflammatory indicators such as C-reactive protein, erythrocyte sedimentation rate, and serum amyloid A were completely normalized at 6 weeks, although there was no statistically significant difference in efficacy among the 3 dose groups. Nine of 15 patients achieved ACR 20 at 6 weeks. At 24 weeks, 13 patients achieved ACR 20 and 5 achieved ACR 50.

Conclusion. Repetitive treatment with MRA was safe and normalized acute phase response in patients with RA. Optimal dosing schedule was not defined in this small study, but maintenance of serum MRA concentration seemed important to achieve efficacy. (J Rheumatol 2003;30:1426–35)

Key Indexing Terms:

RHEUMATOID ARTHRITIS

INTERLEUKIN 6

THERAPY

HUMANIZED ANTI-IL-6 RECEPTOR ANTIBODY

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent synovitis and progressive destruction of cartilage and bone with the presence of rheumatoid factors. RA is also associated with systemic inflammatory manifestations in addition to local inflammation of multiple joints. Although the causes are not fully

understood, many cytokines with inflammatory and joint destructive properties are involved in the development of RA¹⁻³. These inflammatory cytokines are thought to be a potential therapeutic target for treatment.

Interleukin 6 (IL-6) was originally identified as an antigen-nonspecific B cell differentiation factor produced by activated mononuclear cells⁴, and it has been shown to be produced from RA synovial fibroblasts stimulated by tumor necrosis factor (TNF) or IL-1³. Most clinical abnormalities in RA can be accounted for by the unregulated hyperproduction of IL-6¹. It may induce activation of autoreactive T cells and polyclonal hypergammaglobulinemia and emergence of autoantibodies as a result of B cell differentiation⁵⁻⁷. IL-6, as a hepatocyte-stimulating factor, may induce acute phase proteins, resulting in elevation of serum fibrinogen, C-reactive protein (CRP), and amyloid A (SAA) concentrations, and a decrease in serum albumin⁸⁻¹¹. Further, hyperproduction of IL-6 may cause bone absorption through activation of osteoclasts, resulting in osteoporosis and bone destruction¹². IL-6 may induce thrombocytosis by acting as

From the Department of Medical Science I, School of Health and Sport Sciences, Osaka University, Osaka; NTT West Osaka Hospital, Osaka; Nissei Hospital, Osaka; Labor Welfare Corporation Kansai Rousai Hospital, Hyogo; and Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

Supported by Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

N. Nishimoto, MD; K. Yoshizaki, MD, M. Suemura, MD; T. Kishimoto, MD, Osaka University; K. Maeda, MD; T. Kuritani, MD, NTT West Osaka Hospital; H. Deguchi, MD; B. Sato, MD, Nissei Hospital; N. Imai, MD, Labor Welfare Corporation Kansai Rousai Hospital; T. Kakehi, BSc; N. Takagi, MSc, Chugai Pharmaceutical Co., Ltd.

Address reprint requests to Dr. N. Nishimoto, Department of Medical Science I, School of Health and Sport Sciences, Osaka University, 2-1 Yamada-oka, Suita-city, Osaka, 565-0871, Japan.

E-mail: norihiro@imed3.med.osaka-u.ac.jp

Submitted August 12, 2002; revision accepted December 10, 2002.

a megakaryocyte differentiation factor to produce platelets^{13,14}. Indeed, elevation of IL-6 concentrations has been observed in both serum and synovial fluid of patients with RA^{15,16}. Correlation has been observed between serum IL-6 levels and clinical and laboratory indices of RA¹⁷. Wendling, *et al* reported that administration of mouse monoclonal anti-IL-6 antibody to 5 patients with RA for 10 consecutive days resulted in clinical and biological (CRP) improvement although the improvement was transitory¹⁸. Therefore, interference with the action of IL-6 may constitute a new therapeutic strategy for RA.

The IL-6 signal is mediated via the 80 kDa IL-6 receptor (IL-6R) molecule on the cell surface or the soluble form of IL-6R (sIL-6R), followed by dimerization of the 130 kDa signal transducer gp130, which is bound to the IL-6/IL-6R complex^{19,20}. MRA is a humanized anti-human IL-6R monoclonal antibody (Mab) that inhibits the binding of IL-6 to IL-6R or sIL-6R. The effect of MRA was examined in the collagen induced arthritis model with cynomolgus monkeys, because MRA crossreacts with monkey IL-6R but not with rodent IL-6R. MRA inhibited the development of arthritis and improved such inflammatory indicators as CRP, fibrinogen, and erythrocyte sedimentation rate (ESR)²¹. In a SCID mouse model into which synovial tissues from RA patients were implanted, MRA treatment resulted in shrinkage of the implanted tissue and significant reductions in the numbers of inflammatory cells and osteoclasts²².

With patients' informed consent and approval of the Ethical Committee and the Advanced Medical Treatment Review Board of Osaka University, we treated some patients with refractory RA with MRA. The patients received MRA with stepwise dose escalation, mostly up to 50 mg/patient twice a week, with monitoring for safety. The results showed a rapid decrease in CRP to the normal range, and alleviation of joint swelling and tenderness²³.

Based on these findings, we performed a phase I/II open label, dose-ascending trial to evaluate the safety, pharmacokinetics, and efficacy of repetitive intravenous treatment with MRA in patients with established and active RA.

MATERIALS AND METHODS

Patients. The study began in August 1999 and ended in August 2000. Sixteen patients (median age 55 yrs, range 32–72), diagnosed with RA in accord with the 1987 American College of Rheumatology (ACR) criteria and with a history of disease activity for more than 6 months, were enrolled (Table 1). They had failed to respond to at least one of the disease-modifying antirheumatic drugs (DMARD) or immunosuppressants, or were unable to continue the treatments due to adverse reactions. We required patients to have at least 3 swollen joints and at least 6 tender joints, ESR 30 mm/h, serum CRP 2.0 mg/dl, a white blood cell count 3500/ μ l, and platelet count 10^5 / μ l. Pregnant women, nursing women, and women of childbearing potential not using an effective method of contraception were excluded. Patients were also excluded if they had severe disability (Steinbrocker Class IV)²⁴, a history of a serious allergic reaction, any other concurrent collagen disease, significant cardiac, blood, respiratory, neurological, endocrine, renal, hepatic or gastrointestinal disease, or an active intercurrent infection. DMARD and immunosuppressants were discon-

tinued at least 4 weeks before the initial MRA administration. Stable doses of nonsteroidal antiinflammatory drugs and prednisolone (10 mg daily maximum) were allowed. Use of parenteral and/or intraarticular steroid within 4 weeks before the initial MRA administration and during the study period were not permitted. Written informed consent was obtained from each patient before enrollment. The study was approved by the Ministry of Health, Labour and Welfare of Japan and the local ethics committees. Patients were indemnified by the sponsor of the study, Chugai Pharmaceutical Company Ltd., Tokyo.

Study medication and administration. MRA is a humanized anti-human IL-6R Mab of the IgG1 subclass. The antibody was produced by Chugai Pharmaceutical Co. Ltd. by continuous fermentation of Chinese hamster ovary cells, which had been transfected with cloned DNA coding for MRA, and was purified from culture supernatant by a series of column chromatography steps. The MRA retains specificity for human IL-6R and is of high affinity. The antibody was stored at 4°C in 50 ml vials containing 2.5 mg MRA/ml.

The appropriate amount of MRA was diluted to a total volume of 500 ml in sterile saline and administered intravenously with a 0.2 μ m in-line filter. The drug was infused at a rate of about 0.3 ml/min over the first 15 min of infusion, while the patient's condition was closely monitored. If there was no sign of anaphylactic reaction, the rate of infusion was increased. The infusion was performed over a period of 2 h. To ensure safety, patients were carefully monitored during infusion and for at least 1 h after completion. During the first 3 doses, patients were under supervision of the investigator or coinvestigator for at least 24 h after MRA infusion.

This was an open label, dose-ascending study with 3 dose groups, 2, 4, and 8 mg/kg. For each dose, MRA was administered biweekly for 6 weeks, and pharmacokinetics and safety data were collected up to 6 weeks after the first dose. The study was started from the lowest dose, 2 mg/kg. Escalation to the next dose level was permitted if the previous dose level was satisfactory in terms of safety and tolerance as determined by the sponsor after discussion with the sponsor's medical expert and the investigators or coinvestigators. The next higher dose was examined with a group of newly recruited patients. With patients' consent and if MRA treatment was well tolerated and showed an improvement of CRP or ESR compared to baseline, patients were allowed to continue MRA treatment until 24 weeks and were then further assessed for safety and efficacy.

Assessment of safety and efficacy. Safety was monitored until 4 weeks after the last dose. Frequency and severity of adverse effects and adverse drug reactions were observed. Clinical and laboratory tests were performed at screening, at baseline, on dosing day, at 1 week after every dose, and at 4 weeks after last dose. For the first 3 doses, clinical and laboratory tests were also performed on the day after each dose and 2 days after each dose. Laboratory measurements including a complete blood cell count and ESR were performed at each study site. Other laboratory tests were undertaken by the central laboratory, SRL Co., Ltd. Serum levels of MRA were measured with an enzyme immunoassay using MT18 Mab specific for another binding site on IL-6R than that detected by MRA in combination with the sIL-6R. The captured MRA was detected using a biotinylated Mab specific for an epitope in the variable region of MRA, at a dose that does not inhibit the binding of IL-6R. The lowest concentration that could be reliably detected was 1.0 μ g/ml.

The primary efficacy measurements were the changes in CRP and ESR over time, up to 6 weeks after the first infusion. Other efficacy measures were ACR 20, 50, and 70 improvement²⁵ and the change over time in ACR components up to 4 weeks after the last dose.

Statistical methods. For safety analysis, the number of patients who reported adverse events and number of adverse events were recorded for each adverse event for each dose group. Incidence rates of adverse events were calculated with 95% confidence intervals. Pharmacokinetic parameters were calculated from serum MRA concentration data, based on the non-compartment analysis method.

Table 1. Characteristics of the patients at entry.

	MRADose, mg/kg			Total
	2	4	8	
No. of patients	5	5	5	15
Age, yrs, median (range)	55 (40–61)	54 (40–63)	55 (32–72)	55 (32–72)
Sex, M:F	1:4	2:3	1:4	4:11
Duration of disease, yrs, median (range)	10 (4–16)	6 (1–8)	4 (2–25)	7 (1–25)
No. of failed DMARD, median (range)	5 (3–7)	4 (2–6)	4 (2–6)	4 (2–7)
Tender joint counts, mean \pm SD*	26 \pm 17	26 \pm 16	20 \pm 11	24 \pm 14
Swollen joint counts, mean \pm SD*	19 \pm 10	23 \pm 12	19 \pm 9	21 \pm 10
ESR, mm/h, mean \pm SD	92 \pm 24	92 \pm 27	76 \pm 24	87 \pm 25
CRP, mg/dl, mean \pm SD	6.9 \pm 4.5	5.3 \pm 2.4	5.4 \pm 1.8	5.9 \pm 3.0
WBC, per μ l, mean \pm SD	8646 \pm 3068	10722 \pm 1619	10506 \pm 2853	9958 \pm 2587
Platelets, $10^4/\mu$ l, mean \pm SD	30.8 \pm 4.5	32.8 \pm 11.5	48.0 \pm 13.7	37.2 \pm 12.7

*Tender joint count was assessed with 49 joints (maximum joint count was 49). Swollen joint count was assessed with 46 joints (maximum joint count was 46). All values were mean \pm SD. DMARD: disease modifying anti-rheumatic drugs, ESR: erythrocyte sedimentation rate (Westergren); CRP: C-reactive protein, WBC: white blood cell count.

For the efficacy analysis, changes in each of the ACR components, such as CRP, ESR, swollen joint counts, tender joint counts, modified Health Assessment Questionnaire score, physician's global assessment, patient's global assessment, and patient's pain assessment, from baseline for each dose group were analyzed by paired t tests, and mean changes from baseline among the dose groups were analyzed by t tests. The dose relationship was analyzed by appropriate statistical procedures such as Jonckheere's test for trends. Significance was set at $p < 0.05$.

RESULTS

Patients. Sixteen patients were enrolled in the study; their disposition is illustrated in Figure 1. After enrollment, one patient in the 8 mg/kg group was found to have a chest radiograph abnormality and was thus ineligible and was

withdrawn. A total of 15 patients were included in the analysis. Demographic and clinical data at the entry period are summarized in Table 1. The median age was 55 years (range 32–72 yrs) and the median duration of RA was 7 years (range 1–25). The patients had a mean of 24 tender joints (range 8–41) and 21 swollen joints (range 10–35). There were no clinically significant differences among all the dose groups.

Safety. Treatment tolerance of MRA was good. A total of 132 adverse events were reported in all 15 patients analyzed for safety (Table 2 describes adverse events appearing in more than 2 patients). In the 2, 4, and 8 mg/kg groups, there




Figure 1. Disposition of patients through the stages of the study. *Patient was found to be ineligible for study because of a chest radiograph abnormality and was withdrawn before dosing.

Table 2. Adverse events (reported in more than 2 patients in this study).

	MRADose, mg/kg			Total
	2	4	8	
No. of patients	5	5	5	
Blood and lymphatic system disorder				
Iron deficiency anemia	0	1	1	2
General disorder and administration site condition				
Pyrexia	1	0	2	3
Infection and infestations				
Nasopharyngitis	3*	2**	0	5
Tinea blanca	0	2*	2*	4
Blister	0	1*	1	2
Metabolism and nutrition disorder				
Iron metabolism disorder	1	3	2	6
Musculoskeletal connective tissue and bone disorder				
Back pain	1	0	1*	2
Skin/subcutaneous tissue disorder				
Contact dermatitis	0	0	2*	2
Dermatitis NOS	1*	0	1	2
Urticaria NOS	2**	0	0	2
Investigation				
Alanine aminotransferase increased	2	1	0	3
Aspartate aminotransferase increased	1	1	0	2
Blood cholesterol increased	4*	2*	4*	10
Blood glucose increased	4	2	0	6
Blood iron decreased	0	2	0	2
Blood LDH increased	2	3	0	5
Blood pressure increased	1*	1	0	2
Blood thrombin abnormal	1	2	0	3
Blood triglyceride increased	2	1	2*	5
Blood urea increased	2	1	0	3
Glycosuria present	1	1	0	2
Hematuria present	1	1	1	3
Low density lipoprotein increased	4	1	2	7
Leukocyte count decreased	1	1	0	2
Leukocyte count increased	2**	0	0	2
White blood cells in urine	1	1	0	2

* Severity was moderate. ** Severity of one of 2 events was moderate. NOS: not otherwise specified, LDH: lactate dehydrogenase.

were 55, 51, and 26 adverse events, respectively. All adverse events were mild or moderate in severity. A single serious adverse event, herpes zoster, was reported in one patient. This was resolved by medication, and the patient continued the study.

A total of 70 adverse events for which a causal relationship with MRA could not be ruled out (i.e., adverse reaction) were observed in 14 of the 15 patients. During the study period, 37, 20, and 13 adverse reactions were reported in the 2, 4, and 8 mg/kg groups, respectively. Some of the clinical laboratory tests showed dose-dependent changes, but no clear relationship between dose and frequency of adverse reaction was observed. There were 13 adverse events related to skin and subcutaneous tissue disorders (dermatitis, etc.), but no reactions at the injection site were reported. Symptoms associated with the common cold were reported in 5 patients.

In the abnormal laboratory findings, lipid metabolism related reactions such as an increase in blood total cholesterol, low density lipoprotein (LDL), and triglyceride were frequently observed, although they became stable at a certain level and did not continue to increase (Figure 2E–2G). The total cholesterol and LDL cholesterol levels decreased at 24 weeks in the 2 mg/kg group, but there was no statistically significant difference. There was no observation of cardiovascular complications during the study period. Leukocyte and neutrophil counts decreased after MRA administration in all dose groups, but most were within normal range. Two patients showed decrease in leukocyte counts below the normal range, and one of them, in the 2 mg/kg group, had transient, grade 3 neutropenia (neutrophil count < 1000/ μ l) a day after MRA infusion. There were no serious infections associated with transient neutropenia. The patient did not show neutropenia again




Figure 2. Change of ACR components (A–D) and laboratory variables (E–H) in MRAtreated RA patients. Values are mean \pm SD.

during the treatment period. A decrease in serum ferritin concentration was described as iron metabolism disorder, but it was associated with an increase in hemoglobin concentrations, thus indicating effective utilization of iron to hemoglobin synthesis. An increase in blood lactate dehydrogenase was noted in 4 patients. The abnormal laboratory findings did not always persist, and the majority of them spontaneously returned to normal range during the study period.

No allergic reaction related to MRA injection was observed in any patient. Anti-MRA antibodies were not

detected, although most of the patients had circulating concentrations of MRA, which made it difficult to detect anti-MRA antibodies. Antinuclear antibody and anti-DNA antibody were not observed in any patient.

Pharmacology. The individual serum MRA concentrations of this study are shown in Figure 3. Serum MRA concentration was always detectable during the study period in 4 out of 5 patients in the 2 mg/kg group, and 3 out of 5 patients in the 4 mg/kg group. In the 8 mg/kg group, serum MRA concentration could be detected in all periods in all patients.

The mean area-under-the-curve (AUC) and $T_{1/2}$ values




Figure 3. MRA concentration in the sera of patients. MRA was administered intravenously at Weeks 0, 2, and 4. Serum samples were collected before each infusion, at 1 hour after the end of each infusion, at 2 days after each infusion, at 1 week after each infusion, and at 6 weeks after initial infusion. The lowest level that could be reliably detected was 1.0 μ g/ml. All values are mean \pm SD.

are shown in Figure 4. The AUC for the first dose increased as the dose increased and the values (mean \pm SD) were 3.44 ± 8.22 , 4.66 ± 2.18 , and 10.66 ± 4.07 mg \cdot h/ml in the 2, 4, and 8 mg/kg groups, respectively. The serum MRA concentration decreased in a nonlinear manner with the dose range from 2 to 8 mg/kg. The $T_{1/2}$ for the first dose increased as the dose increased; the values (mean \pm SD) were 74.4 ± 18.3 , 96.9 ± 50.2 , and 160.2 ± 34.3 h in the 2, 4, and 8 mg/kg groups, respectively. Multiple infusion also prolonged the $T_{1/2}$, and after the 3rd dose in the 8 mg/kg group reached 241.8 ± 71.4 h.

Clinical efficacy. The mean values of inflammatory indicators such as CRP and ESR are shown in Table 3 and Figures 2A and 2B. Baseline CRP values were 6.9 ± 4.5 , 5.3 ± 2.4 , and 5.4 ± 1.8 mg/dl (mean \pm SD) in the 2, 4, and 8 mg/kg groups, respectively. At 2 weeks after the initial MRA dose, these values decreased to 1.0 ± 0.9 ($p = 0.041$ vs baseline), 2.2 ± 3.0 ($p = 0.028$ vs baseline), and 0.2 ± 0.2 mg/dl ($p = 0.002$ vs baseline), respectively. In the 8 mg/kg group, CRP was normal 2 weeks after initial MRA dose. The baseline ESR values were 92 ± 24 , 92 ± 27 , and 76 ± 24 mm/h, respectively. At 2 weeks, these values decreased to 49 ± 18 ($p = 0.004$ vs baseline), 48 ± 34 ($p = 0.003$ vs baseline), and 15 ± 12 mm/h ($p = 0.002$ vs baseline), respectively. Similar changes were observed in other inflammatory measures. At 24 weeks, these inflammatory measures were further improved. Interestingly, fibrinogen concentrations decreased only to the low-normal range (data not shown). Figure 5 shows individual change from baseline in each inflammatory measure 6 weeks after initial dose. These

objective markers improved markedly in the patients whose serum MRA at the trough levels was detectable, whereas CRP, SAA, and fibrinogen were not completely normalized in the patients whose serum MRA concentrations at trough levels were below the quantification limit throughout the study period.

The baseline serum albumin values were below low-normal range (< 4.0 g/dl) in 12 out of 15 patients, and also at a low limit (4.1 or 4.2 mg/dl) in the remaining 3. This variable showed marked increases, and normalized at 14 weeks at all doses (Figure 2H).

Rheumatoid factors also decreased, from 448.8 ± 431.7 IU/ml at baseline to 176.4 ± 250.4 IU/ml at 14 weeks in the 8 mg/kg group ($p = 0.043$ vs baseline).

The decrease in disease activity is shown in Table 3 and Figures 2C and 2D. The baseline swollen joint counts were 19 ± 10 , 23 ± 12 , and 19 ± 9 (mean \pm SD) in the 2, 4, and 8 mg/kg groups, respectively. At 14 weeks, these values decreased to 12 ± 10 , 8 ± 6 ($p = 0.009$ vs baseline), and 8 ± 4 ($p = 0.045$ vs baseline); and at 24 weeks, to 10 ± 8 ($p = 0.049$ vs baseline), 7 ± 6 ($p = 0.028$ vs baseline), and 5 ± 4 ($p = 0.017$ vs baseline), respectively (Figure 2C). The baseline tender joint counts were 26 ± 16 , 26 ± 16 , and 20 ± 11 in the 2, 4, and 8 mg/kg groups, respectively. These values decreased to 13 ± 13 , 11 ± 14 , and 8 ± 5 at 14 weeks; and to 12 ± 14 , 9 ± 10 , and 8 ± 4 at 24 weeks (Figure 2D). During these periods, the decrease in tender joint counts was statistically significant in the 8 mg/kg group ($p = 0.030$ and $p = 0.028$ vs baseline, respectively). Other ACR components also improved with the MRA treatment. No significant




Figure 4. Pharmacokinetic variables in MRA treated RA patients. Values are mean \pm SD. There was no significant difference between each dose or dosing time.

difference among the treatment groups was observed in the changes of the ACR components.

Improvement rates of the ACR criteria are illustrated in Figure 6. Nine out of 15 patients achieved the ACR 20 at 6 weeks. Two out of 15 patients achieved ACR 50 at 6 weeks. No patient achieved the ACR 70 at 6 weeks in any dose group. At 24 weeks, 13 of 15 patients (> 80%) reached ACR 20, 5 of 15 patients (33%) achieved ACR 50, and 2 of 15 patients (13%) achieved ACR 70. There was no evidence of a statistically significant difference in efficacy among the 3 dose groups.

DISCUSSION

This is the first report of repetitive dosage with MRA for the treatment of RA. Although a total of 70 adverse reactions were reported in the 14 patients during the 24 week treatment, none was severe and there were few infectious

complications. Thus, repetitive treatment with MRA at up to 8 mg/kg biweekly intravenous administration was well tolerated. In the abnormal laboratory data, lipid metabolism abnormalities such as total blood cholesterol, LDL, and triglyceride increases were frequently observed. This finding supports reports that serum cholesterol decreased following administration of recombinant human IL-6 in patients with breast cancer and those with lung cancer^{26,27}. Ettinger, *et al* also reported that IL-6 might suppress apolipoprotein synthesis or secretion²⁸. The inhibition of IL-6 action in the lipid metabolism by MRA might activate apolipoprotein synthesis or secretion, and consequently increase total serum cholesterol and LDL. Another possible explanation is that an increase in total cholesterol may be due to improvement in nutrition or to excessive food intake in response to the decrease in their disease activity. Recently, IL-6 deficient mice were reported to show mature-onset obesity — an increase in body fat and in triglyceride and very low density lipoprotein in the blood — due to suppressed energy expenditure and increased food intake²⁹. Therefore, IL-6 must be an important regulator for lipid metabolism. To date, we do not know whether this phenomenon is specific to IL-6 inhibition in RA. Since high total cholesterol is a risk factor for ischemic heart diseases, longterm followup of patients will be required to define the safety of MRA treatment. The hypoalbuminemia observed as an acute phase reaction was also ameliorated by MRA administration. Considered together with the increase in apolipoprotein, the inhibition of IL-6 action may alleviate the malnutrition due to cachexia in which constitutive overproduction of IL-6 is thought to play an important role³⁰.

With repetitive treatment, MRA accumulated in patients' sera and the $T_{1/2}$ was prolonged at all doses. Thus, it should be possible to extend the interval of MRA administration in repetitive treatment for RA. Further, the advantage of a humanized antibody was emphasized in the repetitive treatment, because there were no allergic reactions related to MRA injection and no anti-MRA antibodies were detected in any patient, none of whom were taking immunosuppressive agents such as methotrexate.

Strong therapeutic efficacy of MRA for established RA was demonstrated in terms of the ACR criteria as outcome measures. The improvement rate for ACR 20 during the entire study period was more than 80% and that of ACR 50 was 33%. Although this was an open label study, the improvement in the inflammatory markers such as CRP and ESR clearly indicates the efficacy of MRA.

Other inflammatory cytokines such as TNF- α and IL-1 β reportedly induce the acute phase proteins *in vitro*. But neither TNF- α inhibitor nor IL-1 receptor antagonist completely normalized CRP and ESR concentrations *in vivo* in patients with RA³¹⁻³⁵. In this study, MRA completely normalized CRP, SAA, and fibrinogen in the RA patients as long as their serum MRA concentrations remained

Table 3. Mean values of ACR component at baseline, Week 2, Week 14, and Week 24 after MRA treatment.

Variable	Baseline	Week 2	Week 14	Week 24
CRP, mg/dl				
2 mg/kg dose	6.9 ± 4.5	1.0 ± 0.9*	0.6 ± 1.2*	0.7 ± 0.9*
4 mg/kg	5.3 ± 2.4	2.2 ± 3.0*	1.3 ± 1.9*	0.3 ± 0.5*
8 mg/kg	5.4 ± 1.7	0.2 ± 0.2*	0.1 ± 0.1*	0.1 ± 0.1*
ESR, mm/h				
2 mg/kg dose	92 ± 24	49 ± 18*	19 ± 12*	22 ± 9*
4 mg/kg	91 ± 27	48 ± 34*	34 ± 27*	23 ± 15*
8 mg/kg	76 ± 24	15 ± 12*	10 ± 6*	10 ± 6*
Swollen joint count				
2 mg/kg dose	19 ± 10	16 ± 12	12 ± 10	10 ± 8*
4 mg/kg	23 ± 12	17 ± 13*	8 ± 6*	7 ± 6*
8 mg/kg	19 ± 9	19 ± 8	8 ± 8*	5 ± 4*
Tender joint count				
2 mg/kg dose	26 ± 16	22 ± 17	13 ± 13*	12 ± 14
4 mg/kg	26 ± 16	22 ± 16	11 ± 14	9 ± 10
8 mg/kg	20 ± 11	19 ± 10	8 ± 5*	8 ± 4*
Physician global assessment**				
2 mg/kg dose	7.9 ± 1.3	6.2 ± 2.5*	3.0 ± 1.1*	2.6 ± 1.4*
4 mg/kg	7.4 ± 2.0	6.0 ± 2.0	4.0 ± 2.0	4.2 ± 2.2
8 mg/kg	8.2 ± 1.7	6.8 ± 2.3	5.0 ± 1.7*	3.7 ± 2.6*
Disability index (MHAQ [†])				
2 mg/kg dose	1.0 ± 0.6	1.7 ± 0.7	0.7 ± 0.4*	0.7 ± 0.5
4 mg/kg	1.3 ± 0.8	1.1 ± 0.7	0.6 ± 0.4	0.6 ± 0.4
8 mg/kg	1.0 ± 0.6	0.7 ± 0.3	0.6 ± 0.4	0.4 ± 0.3
Pain**				
2 mg/kg dose	7.1 ± 2.0	5.8 ± 3.7	2.7 ± 1.6*	2.9 ± 1.8*
4 mg/kg	7.1 ± 1.6	6.2 ± 1.5	4.0 ± 2.3	3.1 ± 1.4*
8 mg/kg	6.5 ± 2.0	5.3 ± 2.3	3.6 ± 2.4*	3.2 ± 2.3*
Patient global assessment**				
2 mg/kg dose	8.1 ± 1.8	6.3 ± 2.9	2.8 ± 1.2*	3.1 ± 2.0*
4 mg/kg	7.8 ± 1.9	6.2 ± 1.7	4.0 ± 1.8*	2.9 ± 1.5*
8 mg/kg	7.1 ± 1.9	5.4 ± 2.4*	3.6 ± 2.3*	3.4 ± 2.6*

* p < 0.05 (paired t test) vs baseline of each assessment. ** Visual analog scale (0 = best, 10 = worst). † Modified Health Assessment Questionnaire (0 = best, 3 = worst). All values were mean ± SD. CRP: C-reactive protein, ESR: erythrocyte sedimentation rate.

detectable. These results indicate that IL-6 is a major cytokine responsible for acute phase protein production *in vivo* in patients with RA. At the same time, MRA was shown to be useful for the treatment of secondary amyloidosis, an important complication in Oriental patients, because only a therapy that successfully reduces the supply of amyloid fibril protein precursors results in substantial regression of amyloid³⁶.

The optimal dosing schedule was not defined in this modest size study, but maintaining the serum MRA concentration was required to obtain the maximum antirheumatic effect and to accomplish complete suppression of inflammatory markers. In the 3 patients treated with 2 mg/kg or 4 mg/kg MRA, MRA was undetectable at trough levels and consequently these patients did not show the maximum response. At this time, we do not know why clearance of serum MRA was more rapid in those patients. They all had high levels of IgG-type rheumatoid factor and high immune

complex in sera before treatment. Since MRA binds to IL-6R, and the immune complex of MRA and IL-6R is cleared by the complement pathway, these patients may rapidly clear immune complexes. However, they also showed significant improvement when they received treatment with 8 mg/kg MRA biweekly after the study periods (data not shown).

We need to address the question whether MRA can prevent joint damage. IL-6 in the presence of sIL-6R can activate osteoclasts *in vitro*¹². SAA was reported to activate matrix metalloproteinase (MMP) synthesis from RA synovial cells, which play an important role in destroying cartilage and bone in the joint³⁷. MRA may prevent joint destruction by inhibiting the osteoclast activation or suppressing SAA and consequently synovial MMP production in patients with RA³⁸. The efficacy of MRA in preventing joint damage remains to be examined in future studies.

In the cytokine network, IL-6 has been shown to have not




Figure 5. Change of inflammatory variables in MRAtreated RA patients. MRA was administered biweekly for 6 weeks (total 15 patients). Each inflammatory variable was compared with baseline and 6 weeks after first the MRA administration period. ●: Serum MRA concentrations were detectable at each predose period (n = 12). △: Serum MRA concentrations were under the detectable limit at each predose period (n = 3).




Figure 6. Overall response to therapy by ACR criteria (n = 15). The number at each bar is the number of patients who reached ACR 20, 50, or 70 criteria. Patients who reached ACR 50 or 70 are also included in ACR 20 and 50, respectively; thus n may be greater than 15.

only proinflammatory but also antiinflammatory properties³⁹. Our data indicate that IL-6 predominantly acts as a proinflammatory cytokine in RA, and blockage of IL-6 signal utilizing MRA suppresses the inflammation. However, the mechanisms by which MRA exerts therapeutic effects for RA are not fully understood. Interactions among cytokines, as well as the actions of an individual cytokine, need to be studied. We also need a double blind, placebo controlled trial of MRA to fully establish efficacy of anti-IL-6 therapy for RA.

ACKNOWLEDGMENT

The authors thank Paul Langman, PhD, for valuable assistance with the preparation of this report.

REFERENCES

1. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. *Ann Rheum Dis* 2000;59 Suppl 1:i21-7.
2. Gabay C. IL-1 inhibitors: novel agents in the treatment of rheumatoid arthritis. *Expert Opin Investig Drugs* 2000;9:113-27.

3. Feldmann M, Brennan FM, Foxwell BM, Maini RN. The role of TNF alpha and IL-1 in rheumatoid arthritis. *Curr Dir Autoimmun* 2001;3:188-99.
4. Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. *J Immunol* 1982;128:1296-301.
5. Ceuppens JL, Baroja ML, Lorre K, Van Damme J, Billiau A. Human T cell activation with phytohemagglutinin. The function of IL-6 as an accessory signal. *J Immunol* 1988;141:3868-74.
6. Lotz M, Jirik F, Kabouridis P, et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. *J Exp Med* 1988;167:1253-8.
7. Hirano T, Taga T, Nakano N, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). *Proc Natl Acad Sci USA* 1985;82:5490-4.
8. Andus T, Geiger T, Hirano T, et al. Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-beta 2) regulates beta-fibrinogen and albumin mRNA levels in Fao-9 cells. *FEBS Lett* 1987; 221:18-22.
9. Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. *Proc Natl Acad Sci USA* 1987;84:7251-5.
10. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. *FEBS Lett* 1988;232:347-50.
11. Isshiki H, Akira S, Sugita T, et al. Reciprocal expression of NF-IL6 and C/EBP in hepatocytes: possible involvement of NF-IL6 in acute phase protein gene expression. *New Biol* 1991;3:63-70.
12. Tamura T, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. *Proc Natl Acad Sci USA* 1993;90:11924-8.
13. Ishibashi T, Kimura H, Uchida T, Kariyone S, Friese P, Burstein SA. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. *Proc Natl Acad Sci USA* 1989;86:5953-7.
14. Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. *Blood* 1989;74:1241-4.
15. Hirano T, Matsuda T, Turner M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. *Eur J Immunol* 1988;18:1797-801.
16. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. *Arthritis Rheum* 1988;31:784-8.
17. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. *Ann Rheum Dis* 1993; 52:232-4.
18. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. *J Rheumatol* 1993;20:259-62.
19. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. *Cell* 1990;63:1149-57.
20. Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. *Science* 1993;260:1808-10.
21. Mihara M, Kotoh M, Nishimoto N, et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. *Clin Immunol* 2001;98:319-26.
22. Matsuno H, Sawai T, Nezuka T, et al. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model. *Arthritis Rheum* 1998;41:2014-21.
23. Yoshizaki K, Nishimoto N, Mihara M, Kishimoto T. Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody. *Springer Semin Immunopathol* 1998;20:247-59.
24. Steinbrocker O, Traeger CH, Battersman RC. Therapeutic criteria in rheumatoid arthritis. *JAMA* 1994;271:1443-53.
25. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727-35.
26. van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. *Blood* 1994;84:1434-41.
27. Veldhuis GJ, Willemse PH, Sleijfer DT, et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. *J Clin Oncol* 1995;13:2585-93.
28. Ettlinger WH, Varma VK, Sorci-Thomas M, et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. *Arterioscler Thromb* 1994;14:8-13.
29. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. *Nat Med* 2002;8:75-9.
30. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. *Med Res Rev* 1999;19:223-48.
31. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. *Arthritis Rheum* 1993;36:1681-90.
32. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. ATTRACT Study Group. *N Engl J Med* 2000;343:1594-602.
33. Bresnihan B, Alvaro-Gracia JM, Cobby M. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum* 1998;41:2196-204.
34. Moreland LW, Schiff MH, Baumgartner SW. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med* 1999;130:478-86.
35. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. *J Immunol* 1999;163:1521-8.
36. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. *Lancet* 2001;358:4-5.
37. Martel-Pelletier J, Welsch DJ, Pelletier JP. Metalloproteinases and inhibitors in arthritic diseases. *Best Pract Res Clin Rheumatol* 2001;15:805-29.
38. Migita K, Kawabe Y, Tominaga M, Origuchi T, Aoyagi T, Eguchi K. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. *Lab Invest* 1998;78:535-9.
39. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. *J Clin Invest* 1998;101:3111-20.